XENE - Xenon Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.01
-0.06 (-0.60%)
As of 2:28PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close10.07
Open10.01
Bid9.83 x 1100
Ask10.03 x 1400
Day's Range9.81 - 10.30
52 Week Range5.41 - 15.92
Volume15,713
Avg. Volume84,675
Market Cap257.988M
Beta (3Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-1.81
Earnings DateMar 5, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.33
Trade prices are not sourced from all markets
  • Do Institutions Own Shares In Xenon Pharmaceuticals Inc. (NASDAQ:XENE)?
    Simply Wall St.8 days ago

    Do Institutions Own Shares In Xenon Pharmaceuticals Inc. (NASDAQ:XENE)?

    Every investor in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) should be aware of the most powerful shareholder groups...

  • Hedge Funds Have Never Been This Bullish On Xenon Pharmaceuticals Inc (XENE)
    Insider Monkeylast month

    Hedge Funds Have Never Been This Bullish On Xenon Pharmaceuticals Inc (XENE)

    Does Xenon Pharmaceuticals Inc (NASDAQ:XENE) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend […]

  • GlobeNewswirelast month

    Xenon Pharmaceuticals Presents Corporate Update on Neurology-Focused Pipeline at the Jefferies 2019 Healthcare Conference

    Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a business update today at the Jefferies 2019 Healthcare Conference in New York, NY at 11:00 am ET. The presentation will focus on the company’s proprietary clinical stage epilepsy products, including XEN496, XEN1101, and XEN901, and will highlight recent regulatory feedback guiding the clinical development of XEN901, a potent, highly selective Nav1.6 sodium channel inhibitor being developed for the treatment of epilepsy.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of XENE earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Xenon Pharmaceuticals Inc Earnings Call

  • GlobeNewswire2 months ago

    Xenon Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

    BURNABY, British Columbia, May 29, 2019 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone,.

  • Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Overpaying Its CEO?
    Simply Wall St.2 months ago

    Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Overpaying Its CEO?

    Simon Pimstone has been the CEO of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) since 2003. This report will, first...

  • Xenon Pharmaceuticals Inc. (XENE) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Xenon Pharmaceuticals Inc. (XENE) Q1 2019 Earnings Call Transcript

    XENE earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    Xenon Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 42 cents. Xenon Pharmaceuticals shares have increased 51% since the beginning of the year. In the final minutes of ...

  • GlobeNewswire2 months ago

    Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

    Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in Phase 2 or Later Stage Development this Year Conference Call at 4:30 pm ET Today.

  • GlobeNewswire3 months ago

    Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update

    Xenon Pharmaceuticals Inc. (XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2019 financial and operating results after the close of U.S. financial markets on Tuesday, May 7, 2019.  Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 7268384.

  • GlobeNewswire3 months ago

    Xenon Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

    BURNABY, British Columbia, April 24, 2019 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone,.

  • Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Immense Growth Potential?
    Simply Wall St.3 months ago

    Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Immense Growth Potential?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its most recent earnings announcement, which signall...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of XENE earnings conference call or presentation 6-Mar-19 9:30pm GMT

    Full Year 2018 Xenon Pharmaceuticals Inc Earnings Call

  • GlobeNewswire4 months ago

    Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update

    Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2018 and provided a corporate update. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “2018 was a pivotal year for Xenon as we built out our neurology pipeline and advanced multiple CNS product candidates using a variety of development strategies, including a ‘precision medicine’ approach to address rare pediatric disorders. Dr. Pimstone continued, “We have taken great care to create a diverse portfolio of therapeutic candidates, with a common focus on addressing neurological disorders.

  • ACCESSWIRE4 months ago

    Xenon Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 6, 2019 / Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 6, 2019 at 4:30 ...

  • Benzinga4 months ago

    The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on March 5) AstraZeneca plc (NYSE: AZN ) Biohaven Pharmaceutical ...

  • GlobeNewswire5 months ago

    Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update

    Xenon Pharmaceuticals Inc. (XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2018 financial and operating results after the close of U.S. financial markets on Wednesday, March 6, 2019.  Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 1545448.

  • Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
    PR Newswire5 months ago

    Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

    SAN FRANCISCO, Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin Pharmaceutical Inc. (BMRN), Invitae Corporation (NVTA), Stoke Therapeutics and Xenon Pharmaceuticals (XENE) today announced the expansion of Behind the Seizure, an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. Previously available to patients ages 2-4 years, the program will expand eligibility to make no-cost genetic testing available for healthcare providers to order for children who have had an unprovoked seizure from birth up to age five (0 to 60 months).

  • GlobeNewswire6 months ago

    Xenon Provides Key Regulatory Updates on XEN007 and XEN1101

    BURNABY, British Columbia, Jan. 28, 2019 (GLOBE NEWSWIRE) --  Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided regulatory updates on XEN007 and XEN1101, two therapeutic candidates from its CNS pipeline. The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease (RPD) designation for the treatment of Alternating Hemiplegia of Childhood (AHC) with XEN007 (active ingredient flunarizine).

  • What Kind Of Shareholder Owns Most Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock?
    Simply Wall St.6 months ago

    What Kind Of Shareholder Owns Most Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock?

    Every investor in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...

  • GlobeNewswire6 months ago

    Xenon Pharmaceuticals Outlines 2019 Key Milestones

    Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key milestone events in 2019. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “Xenon is entering 2019 in a strong position, poised to support multiple neurology programs that are expected to be in Phase 2 or later stage development this year. With four distinct therapeutic candidates – XEN496, XEN1101, XEN901 and XEN007 – that are aimed at treating neurological disorders, including epilepsy, we intend to pursue a variety of development strategies, such as those focused on using a ‘precision medicine’ approach to address rare pediatric disorders including KCNQ2 epilepsy as well as those targeting broader patient populations, including adult patients with focal epilepsy.

  • Eversept Partners’ Return, AUM, and Holdings
    Insider Monkey7 months ago

    Eversept Partners’ Return, AUM, and Holdings

    Eversept Partners is a New York-based hedge fund that focuses on investing in companies from the healthcare sector. It was founded by its current portfolio manager Mr. Kamran Moghtaderi, who previously worked as an Analyst and Portfolio Manager at Apis Capital Advisors, LLC. Mr. Moghtaderi’s investment experience is much more extensive than this, as prior […]

  • Xenon Pharmaceuticals Inc (XENE): Are Hedge Funds Right About This Stock?
    Insider Monkey7 months ago

    Xenon Pharmaceuticals Inc (XENE): Are Hedge Funds Right About This Stock?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • GlobeNewswire7 months ago

    Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

    Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided clinical updates on XEN1101, a Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders and XEN901, a potent, highly selective Nav1.6 sodium channel inhibitor being developed for the treatment of epilepsy. Xenon announced final results from its XEN1101 Phase 1 clinical trial and the related transcranial magnetic stimulation (TMS) studies, along with interim results from its XEN901 Phase 1 clinical trial, in posters at the American Epilepsy Society (AES) Annual Meeting held in New Orleans, LA.

  • GlobeNewswire8 months ago

    Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

    BURNABY, British Columbia, Nov. 30, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference.